Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
Date:3/11/2011

expenses totaled $7.3 million in the fourth quarter of 2010, compared to $6.5 million in the fourth quarter of 2009, and $27.9 million in the full year ended December 31, 2010, compared to $25.2 million in the full year ended December 31, 2009. This increase is primarily attributable to expenses related to litigation and increased patent fees. General and administrative expenses in the full year ended December 31, 2010, included $2.1 million in non-cash, share-based compensation expense, compared to $2.8 million in 2009.

Total interest and other expense increased to $28.2 million in the full year ended December 31, 2010, compared to $14.8 million in 2009. This increase is primarily attributable to increases in the loss on extinguishment of debt, a non-cash item, and interest expense, both related to Arena's loan from certain Deerfield entities.

At December 31, 2010, cash and cash equivalents totaled $150.7 million and approximately 121.5 million shares of common stock were outstanding.

Arena's Recent and Fourth Quarter 2010 Developments Lorcaserin

  • Received a complete response letter from the US Food and Drug Administration (FDA) regarding the lorcaserin New Drug Application (NDA), completed an end-of-review meeting with the FDA and reported on Arena and Eisai's plans related to resubmitting the NDA.
  • Announced top-line results from the Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial, which evaluated lorcaserin for weight management in obese and overweight patients with type 2 diabetes. Lorcaserin met the three primary efficacy endpoints, and Arena believes the results favorably support the benefit-risk profile of lorcaserin.
  • Presented at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society, results from a lorcaserin mechanism of action study conducted at the Pennington Biomedical Research Center. The data showed t
    '/>"/>

  • SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
    2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
    3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
    4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
    5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
    6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
    7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
    8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
    9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
    10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
    11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... - The Canadian Epilepsy Alliance (CEA) is thrilled to announce ... children about the most common neurological disorder in ... comic series tells a fictional story based on the experiences ... with epilepsy. "Despite the fact that epilepsy ... misinformation and lack of awareness out there," says Gail ...
    (Date:8/21/2014)... , Aug. 21, 2014  IBM (NYSE: IBM ... ( DESY ), a leading national research center in ... and storage of massive volumes of x-ray data. The ... on IBM software defined technology can handle more than ... and help scientists worldwide gain faster insights into the ...
    (Date:8/21/2014)... , Aug. 21, 2014  Zacks.com announces the list of ... Equity Research analysts discuss the latest news and events impacting ... blog include the Hewlett-Packard (NYSE: HPQ - Free Report ), ... Inc. (NYSE: SB - Free Report ), GlaxoSmithKline plc ... N.V. (NYSE: FI - Free Report ). ...
    Breaking Medicine Technology:Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11
    (Date:8/22/2014)... FL (PRWEB) August 22, 2014 This ... cell therapy research affiliate, Saneron CCEL Therapeutics, Inc. in ... , “Cryo-Cell is extremely pleased to collaborate with Saneron ... IND, which we hope will lead to regenerative ... diseases such as ALS,” David Portnoy, Chairman and Co-CEO ...
    (Date:8/22/2014)... 2014 (HealthDay News) -- The air in American cities ... Agency reported Thursday. Significant progress has been made ... in recent decades, the agency said in a news ... 60 percent reduction in mercury from human sources such ... and an 84 percent fall in lead, which harms ...
    (Date:8/22/2014)... may reduce addiction without increasing exposure to toxic ... University of Waterloo. , The study published ... the smoking behaviours of 72 adults as they ... reduced nicotine levels. , Unlike when smokers switch ... similar levels of nicotine contentthe study found no ...
    (Date:8/22/2014)... (PRWEB) August 22, 2014 Goats are taking ... Milk Foods, attends the 10th annual Pre-Emmy Awards Boom Boom ... to try the best new products for kids on August ... 4 p.m., and we’ll be encouraging them to #GoGoat for ... so excited to present our gentle, non-GMO goat milk foods ...
    (Date:8/22/2014)... (PRWEB) August 22, 2014 For the ... employee reward and recognition industry, has received a prestigious ... extraordinary growth rate of 134%, TharpeRobbins remains on the ... North America. TharpeRobbins was previously on the list in ... to be included in this distinguished list for a ...
    Breaking Medicine News(10 mins):Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 2Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 3Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2Health News:Smokers consume same amount of cigarettes regardless of nicotine levels 2Health News:#GoGoat with Kabrita at the Pre-Emmy Awards Boom Boom Room 2Health News:For The Fourth Time - TharpeRobbins Earns A Place On Prestigious Inc. Magazine 500|5000 List 2Health News:For The Fourth Time - TharpeRobbins Earns A Place On Prestigious Inc. Magazine 500|5000 List 3
    ... July 9, 2009 The President of the ... statement today on President Obama,s nomination of Francis Collins, M.D., ... Health (NIH):,"At no other time in recent memory has there ... in the power of science to deliver solutions to the ...
    ... Bioheart, Inc. (OTC Bulletin Board: BHRT) (the "Company") ... July 7, 2009, Bioheart, Inc. (the "Company") has received proceeds ... common stock and warrants under its current offering under Regulation ... Common Stock to be issued in connection with the Offering ...
    ... Parsippany took top honors in the state,s first-ever 100-day ... on June 2nd. With participating residents losing an average of ... pounds, Parsippany was presented with a plaque and Morris County ... , Residents throughout northern and central New Jersey also participated ...
    ... , ... and Directory Helps Attendees and Exhibitors,Connect at AAMSE Conference and Beyond. , ... Arlington, VA (PRWEB) July 9, 2009 -- MarketArt ... enhanced attendee experience at the American Association of Medical Society Executives (AAMSE) 2009 ...
    ... Institute of Technology (Caltech) and the Scripps Research Institute have ... chemicals that have the potential to take the place of ... James R. Heath, the Elizabeth W. Gilloon Professor and ... M. Keck Professor of Chemistry at the Scripps Research Institute ...
    ... United States Senate Committee on Small Business ... Member Olympia J. Snowe, R-Maine, today convened a ... relate to small businesses. Participants at the roundtable, ... the Perspective of Small Businesses," included U.S. Sen. ...
    Cached Medicine News:Health News:Bioheart, Inc. Announces Receipt of $2.8 Million in Proceeds From Pipe Financing 2Health News:Bioheart, Inc. Announces Receipt of $2.8 Million in Proceeds From Pipe Financing 3Health News:Parsippany Takes Top Honors in New Jersey's First-Ever Toxic Waistlines Contest 2Health News:Parsippany Takes Top Honors in New Jersey's First-Ever Toxic Waistlines Contest 3Health News:MarketArt to Enhance Attendee Experience at AAMSE Annual Conference 2Health News:MarketArt to Enhance Attendee Experience at AAMSE Annual Conference 3Health News:Caltech chemists say antibody surrogates are just a 'click' away 2Health News:Caltech chemists say antibody surrogates are just a 'click' away 3Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 2Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 3
    Mounted on a remarkably lightweight and,flexible cotton headband with crown strap,the Sport is fully adjustable....
    ... putty is a product of AlloSource, ... in human tissue processing, and Interpore ... technology. InterGro combines AlloGro DBM ... to deliver a unique bone graft ...
    ... bone content (93% by volume) of any ... excellent handling characteristics, which will enhance any ... alone or as a graft extender for ... The high molecular weight biocompatible carrier allows ...
    ... DS Strep A is a qualitative assay for ... swabs. The ICON DS Strep A test excels ... rare and low positive colonization samples. This CLIA ... outstanding performance, ICON DS Strep A leaves little ...
    Medicine Products: